Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients

BRAF-mutated colorectal cancer, primarily driven by the BRAF V600E mutation, accounts for approximately 5-10% of all colorectal cancer cases and is associated with aggressive disease progression and poor prognosis, particularly in metastatic settings. Following first- and second-line treatments, including chemotherapy and targeted therapy, the median overall survival of patients is typically less than 24 months, and tumor progression is rapid once resistance develops. Previous studies have demonstrated that immune checkpoint inhibitors, such as anti-PD-1 therapies, show limited efficacy in mic

Trial Details

NCT ID

NCT07809893

Phase

PHASE2

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Colon Cancer Colorectal Cancer

Interventions

• Ivonescimab +mFOLFOXIRI +celecoxib

Locations (sample)

• Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

• Signed the informed consent form voluntarily.
• Aged 18-70.
• Colorectal adenocarcinoma with definite histological evidence, with evidence of distant metastasis;
• Diagnosed with colon or rectal adenocarcinoma, with evidence of distant metastasis;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →